You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Cathepsin Inhibitors for Treatment of Breast Cancer Induced Bone Pain
SBC: VIROBAY, INC. Topic: NCIDESCRIPTION (provided by applicant): The World Health Organization estimates that the number of women living with breast cancer globally will rise to 15 million by the year 2020 with a significant portion of these patients in advanced stages of the disease. Breast cancer is the most frequent malignant tumor in women in the U.S. with nearly 200,000 women diagnosed each year. The U.S. NIH estimate o ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Lateral Flow Immunoassays For Pharmacokinetic Dosing Of Monoclonal Antibodies
SBC: ABREOS BIOSCIENCES, INC. Topic: NCIDESCRIPTION (provided by applicant): Monoclonal antibodies (mAb) are used to treat a variety of cancers and other diseases. Dosing is typically based on body surface area, but population pharmacokinetic (PK) data suggests considerable variation across patients. Furthermore, there is growing evidence that patients with low final trough levels of circulating antibody have a poorer outcome, suggestin ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Efficacy of Silicon-based Dual Energy CT Contrast Material
SBC: NEXTRAST, INC Topic: NIDDKDESCRIPTION (provided by applicant): Our long term goal is to revolutionize the safety and effectiveness of computed tomography (CT) imaging for millions of Americans across a broad range of gastrointestinal disease. Bowel and intravenous contrast materials improve the CT imaging of abdominal disease. Unfortunately, none of the current clinical contrast materials are visibly different from the oth ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Manufacture of Self-Reporting, Drug Loaded Porous Silicon Nanomaterials for Treat
SBC: SPINNAKER BIOSCIENCES, INC. Topic: NEIPROJECT SUMMARY/ABSTRACT Visual impairment is a global epidemic affecting millions of individuals currently. A large portion of these individuals suffer from chronic age-related macular degeneration (AMD), characterized by progressive neovascularization and vascular leakage near the central region (macula) of the retina. Current treatments for AMD, including laser photocoagulation, photodynamic th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
High Z Oraya Therapy for wet AMD
SBC: ORAYA THERAPEUTICS, INC Topic: NEIProject Description The purpose of this project is to develop a new radiotherapy treatment modality that will substantially enhance the treatment of wet AMD with minimal toxicity to healthy tissue, leading to major improvement in visual acuity, decreaseduse of intravitreal injections of anti-VEGF agents, lower cost of treatment, and a substantially improved quality of life for patients. The new m ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Advanced Assessment to Accelerate Diagnostic Skill Acquisition
SBC: Parallel Consulting, LLC Topic: NIGMSDESCRIPTION (provided by applicant): Current approaches to medical education produce new physicians with insufficient clinical competency to practice effectively with limited supervision, which has serious implications for patient outcomes during hospitaloff hours. Up to 70% of patients admitted to a hospital are admitted on nights or weekends, when staffing is low and residents may be in charge o ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Modernize animal pharming with emerging gene targeting technologies
SBC: APPLIED STEMCELL, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Animal pharming is the process of using transgenic animals to produce human drugs, mostly in the mammary glands of female animals. The US Food and Drug Administration (FDA) issued its first approval for ATryn, the recombinant human antithrombin III, produced in the milk of transgenic goats in 2009. Prior to FDA approval, this drug gained the approval by the Eu ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Perceptually Accurate Video Manipulation of Vehicle Speed for Teen Driver Training
SBC: Parallel Consulting, LLC Topic: NICHD? DESCRIPTION (provided by applicant): Motor vehicle crashes are the leading cause of death and injury for teens, accounting annually for over 3000 deaths, 100 times as many injuries, and over 14 billion dollars in associated costs. Speeding contributes to more than 30% of teen driving crashes and is the primary factor in over 20% of serious teen crashes. Among teens, driving too fast for cond ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Amplification-free megabase target-enrichment for next-generation sequencing
SBC: MISSION BIO INC Topic: NHGRIDESCRIPTION (provided by applicant): Target enrichment for next-generation sequencing enables researchers to reduce the burden of sequence data analysis, obtain higher levels of statistical significance by examining more genomes and increase sequencing coverage depth. The goal of this STTR proposal is to develop and commercialize a novel technology capable of amplification-free megabase target seq ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LUNG INJURY AND FIBROSIS
SBC: XFIBRA, LLC Topic: NHLBIDESCRIPTION (provided by applicant): Activation of lung myofibroblasts (LMF) is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably, LMF clearance by apoptosis may prevent development of lung fibrosis andlung injury, and possibly allow recovery from reversal of lung fibrosis. There is full agreement among tissue fibrosis experts that inhibiting o ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health